Literature DB >> 25575724

[Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma].

G J Wengert1, H Bickel, J Breitenseher, A Ba-Ssalamah.   

Abstract

CLINICAL ISSUE: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (ICC) are the most commonly occurring and important primary liver tumors. Originating from one pluripotent liver stem cell both tumor entities can occur in a cirrhotic liver and also in patients without cirrhosis. Several risk factors have been identified as causative for both carcinomas; therefore, tumor screening is advantageous, especially for high-risk patients who could be diagnosed in an early stage to allow curative treatment. Surgical resection, interventional procedures and transplantation are available as curative treatment options when diagnosed in time. STANDARD RADIOLOGICAL
METHODS: Common characteristic features and morphology in cross-sectional imaging by ultrasound (US), multidetector computed tomography (CT) and magnetic resonance imaging (MRI) as well as screening aspects are presented and discussed. METHODICAL INNOVATIONS: Recent findings show a better understanding of the carcinogenesis model of both liver tumors originating from one pluripotent liver stem cell. Further developments of modern cross-sectional imaging modalities, especially MRI in combination with diffusion-weighted imaging and intravenous administration of hepatocyte-specific contrast agents enable early detection, exact differentiation, staging and treatment evaluation of HCC and ICC ACHIEVEMENTS: In this article we discuss modern, multiparametric imaging modalities, which allow a complete and reliable diagnosis of the majority of these tumor entities. PRACTICAL RECOMMENDATIONS: Contrast-enhanced MRI, using hepatocyte-specific contrast agents, is currently the most accurate procedure for the noninvasive diagnosis and treatment evaluation of HCC and ICC.

Entities:  

Mesh:

Year:  2015        PMID: 25575724     DOI: 10.1007/s00117-014-2705-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  42 in total

1.  Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography.

Authors:  Toshifumi Tada; Takashi Kumada; Hidenori Toyoda; Takanori Ito; Yasuhiro Sone; Seiji Okuda; Sadanobu Ogawa; Takumi Igura; Yasuharu Imai
Journal:  J Gastroenterol       Date:  2014-02-22       Impact factor: 7.527

2.  Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Authors:  Y S Chong; Y K Kim; M W Lee; S H Kim; W J Lee; H C Rhim; S J Lee
Journal:  Clin Radiol       Date:  2012-03-15       Impact factor: 2.350

3.  Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.

Authors:  Sayaka Sekiya; Atsushi Suzuki
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

4.  Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation.

Authors:  Hyeon Tae Jeong; Myeong-Jin Kim; Yong Eun Chung; Jin Young Choi; Young Nyun Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

5.  Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging.

Authors:  Chen-Te Chou; Jung-Mao Chou; Ting-An Chang; Shiu-Feng Huang; Chia-Bang Chen; Yao-Li Chen; Ran-Chou Chen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 6.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

7.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

Review 8.  Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features.

Authors:  Robert F Hanna; Diego A Aguirre; Norbert Kased; Shawn C Emery; Michael R Peterson; Claude B Sirlin
Journal:  Radiographics       Date:  2008 May-Jun       Impact factor: 5.333

Review 9.  Systemic therapy of hepatocellular carcinoma: current status and future perspectives.

Authors:  Domenico Germano; Bruno Daniele
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

Review 1.  [CEUS-Diagnostic of malignant liver lesions].

Authors:  G Negrão de Figueiredo; K Müller-Peltzer; J Rübenthaler; D A Clevert
Journal:  Radiologe       Date:  2018-06       Impact factor: 0.635

2.  Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study.

Authors:  Jun Luo; Jiaping Zheng; Changsheng Shi; Jian Fang; Zhiyi Peng; Jing Huang; Junhui Sun; Guanhui Zhou; Tiefeng Li; Dedong Zhu; Huanhai Xu; Qinming Hou; Shihong Ying; Zhichao Sun; Haijun Du; Xiaoxi Xie; Guohong Cao; Wenbin Ji; Jun Han; Wenjiang Gu; Xiaohua Guo; Guoliang Shao; Zhihai Yu; Jian Zhou; Wenqiang Yu; Xin Zhang; Ling Li; Hongjie Hu; Tingyang Hu; Xia Wu; Yutang Chen; Jiansong Ji; Wenhao Hu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.